Group items tagged

Biotech sector stocks saw major gains and sharp falls on heavy trading as mixed news hit the markets, ranging from a positive court ruling to the death of two study participants.

While biotech is not an industry for investors who are faint of heart, the potential for big returns can still make it attractive.

Stock in biotech company Medivation more than doubled in value after reports that their phase III study of a new drug to treat prostate cancer has showed major success.

This article discusses a handful of penny stocks with exposure to potential Alzheimer's disease treatments. The bullish sympathy trend has come to light following late-breaking news on Tuesday that Biogen (NASDAQ: BIIB) and Eisai Co.'s experimental Alzheimer's drug significantly slowed the progression of the disease in a large study. The 18-month, Phase 3 study of 1,800 patients tested the treatment on early-stage Alzheimer's patients. 4 more Alzheimer's stocks to watch

Robert Maltbie of Singular Research shares his firm's best idea of the week. This innovative biotech company has a proven product and is about to ramp up market share growth.

Onyxx,Merck and Biogen are all trading higher on elevated volume as announcements at the respective companies bode well for future sales. There is reason to believe all three of the companies will benefit from the latest news.

Chuck Carnevale uses is F.A.S.T. Graphs™ fundamental analysis to break down a global biotech company that could realize its potential for significant growth.

Ken Calhoun discusses how to use sector performance in identifying possible false breakouts in today's market. Traders can drill down for target stocks with this method.

The Healthcare sector has been particularly busy in the first month of 2012 with a healthy dose of major acquisitions dominating the news.